On Tuesday, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) opened lower -3.86% from the last session, before settling in for the closing price of $24.88. Price fluctuations for ARWR have ranged from $20.67 to $39.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 205.96%. Company’s average yearly earnings per share was noted -59.65% at the time writing. With a float of $117.64 million, this company’s outstanding shares have now reached $124.20 million.
Let’s determine the extent of company efficiency that accounts for 525 employees.
Arrowhead Pharmaceuticals Inc. (ARWR) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arrowhead Pharmaceuticals Inc. is 5.28%, while institutional ownership is 77.22%. The most recent insider transaction that took place on May 02 ’24, was worth 41,935. In this transaction Director of this company sold 1,799 shares at a rate of $23.31, taking the stock ownership to the 30,205 shares. Before that another transaction happened on Apr 01 ’24, when Company’s Chief Discovery/Trans Medicine sold 6,000 for $28.03, making the entire transaction worth $168,180. This insider now owns 204,851 shares in total.
Arrowhead Pharmaceuticals Inc. (ARWR) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 3/31/2024, the company posted -0.96 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.65) by -0.31. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -59.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.33% during the next five years compared to -24.19% drop over the previous five years of trading.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Trading Performance Indicators
Check out the current performance indicators for Arrowhead Pharmaceuticals Inc. (ARWR). In the past quarter, the stock posted a quick ratio of 8.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 83.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.24, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -2.71 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc. (ARWR)
Looking closely at Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), its last 5-days average volume was 0.7 million, which is a drop from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 51.99%. Additionally, its Average True Range was 1.26.
During the past 100 days, Arrowhead Pharmaceuticals Inc.’s (ARWR) raw stochastic average was set at 13.72%, which indicates a significant decrease from 51.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.49% in the past 14 days, which was higher than the 63.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.02, while its 200-day Moving Average is $28.05. However, in the short run, Arrowhead Pharmaceuticals Inc.’s stock first resistance to watch stands at $25.05. Second resistance stands at $26.18. The third major resistance level sits at $27.00. If the price goes on to break the first support level at $23.10, it is likely to go to the next support level at $22.28. Should the price break the second support level, the third support level stands at $21.15.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Key Stats
There are currently 124,200K shares outstanding in the company with a market cap of 2.97 billion. Presently, the company’s annual sales total 240,740 K according to its annual income of -205,280 K. Last quarter, the company’s sales amounted to 3,550 K and its income totaled -132,860 K.
